Several other brokerages have also commented on BLUE. Roth Capital began coverage on shares of Bluebird Bio in a report on Thursday, September 22nd. They issued a buy rating and a $87.00 price target for the company. Maxim Group set a $85.00 target price on shares of Bluebird Bio and gave the stock a buy rating in a report on Thursday, September 22nd. Zacks Investment Research lowered shares of Bluebird Bio from a hold rating to a sell rating in a report on Wednesday, October 5th. Jefferies Group reaffirmed a buy rating and set a $80.00 target price on shares of Bluebird Bio in a report on Friday, September 23rd. Finally, Wedbush reaffirmed an outperform rating and set a $117.00 target price on shares of Bluebird Bio in a report on Monday, October 3rd. One analyst has rated the stock with a sell rating, four have assigned a hold rating and fourteen have given a buy rating to the company’s stock. Bluebird Bio currently has a consensus rating of Buy and an average price target of $91.60.
Shares of Bluebird Bio (NASDAQ:BLUE) opened at 54.90 on Thursday. Bluebird Bio has a one year low of $35.37 and a one year high of $99.70. The company’s market cap is $2.04 billion. The company’s 50-day moving average is $63.92 and its 200-day moving average is $51.26.
Bluebird Bio (NASDAQ:BLUE) last issued its quarterly earnings results on Wednesday, August 3rd. The company reported ($1.59) EPS for the quarter, missing the consensus estimate of ($1.44) by $0.15. The company earned $1.55 million during the quarter, compared to analysts’ expectations of $2.01 million. Bluebird Bio had a negative return on equity of 24.85% and a negative net margin of 3,512.13%. Bluebird Bio’s revenue was down 68.6% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.57) EPS. On average, equities analysts predict that Bluebird Bio will post ($6.19) EPS for the current year.
In other Bluebird Bio news, insider Eric Sullivan sold 416 shares of the company’s stock in a transaction dated Monday, October 3rd. The shares were sold at an average price of $67.00, for a total value of $27,872.00. Following the transaction, the insider now owns 5,891 shares of the company’s stock, valued at $394,697. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 3.50% of the stock is currently owned by company insiders.
Several hedge funds have recently modified their holdings of BLUE. Wellington Management Group LLP acquired a new stake in shares of Bluebird Bio during the first quarter valued at about $51,095,000. BlackRock Fund Advisors boosted its stake in shares of Bluebird Bio by 80.0% in the second quarter. BlackRock Fund Advisors now owns 1,386,229 shares of the company’s stock valued at $60,010,000 after buying an additional 616,095 shares in the last quarter. State Street Corp boosted its stake in shares of Bluebird Bio by 41.4% in the second quarter. State Street Corp now owns 1,699,977 shares of the company’s stock valued at $73,592,000 after buying an additional 498,041 shares in the last quarter. RTW Investments LLC boosted its stake in shares of Bluebird Bio by 170.4% in the second quarter. RTW Investments LLC now owns 612,025 shares of the company’s stock valued at $26,495,000 after buying an additional 385,654 shares in the last quarter. Finally, Deerfield Management Co. acquired a new stake in shares of Bluebird Bio during the second quarter valued at about $14,636,000.
About Bluebird Bio
bluebird bio, Inc is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.
Receive News & Ratings for Bluebird Bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluebird Bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.